498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

• Tae Min Kim,
• Yung-Jue Bang,
• Keun-Wook Lee,
• Patricia LoRusso,
• Wells Messersmith,
• Feng Jin,
• Nehal Lakhani,
• Alison Forgie,
• Justin Gainor,
• Jaume Pons,
• Hong Wan,
• Pierre Squifflet,
• Laura Chow,
• Philip Fanning,
• Sophia Randolph,
• Hyun Chung,
• Rafael Santana-Davila,
• Won Seog Kim

Affiliations

Tae Min Kim

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Yung-Jue Bang

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

Keun-Wook Lee

Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, South Korea

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

Wells Messersmith

1University of Colorado School of Medicin, Aurora, CO, USA

Feng Jin

5 Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Nehal Lakhani

4START Midwest, Grand Rapids, MI, USA

Alison Forgie

12Pfizer, San Francisco, CA, USA

Justin Gainor

8Mass General Hospital, Boston, MA, USA

Jaume Pons

3ALX Oncology, Inc., Burlingame, CA, USA

Hong Wan

1Tallac Therapeutics, Burlingame, CA, USA

Pierre Squifflet

International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium

Laura Chow

10University of Texas Austin, Austin, TX, USA

Philip Fanning

6ALX Oncology, Inc, Burlingame, CA, USA

Sophia Randolph

6ALX Oncology, Inc, Burlingame, CA, USA

Hyun Chung

2Yonsei Cancer Center, Seoul, Korea, Republic of

Rafael Santana-Davila

6University of Washington, Seattle, WA, United States

Won Seog Kim

7Samsung Medical Center, Seoul, Korea, Republic of